G.P. Talwar
Many years back, I developed a vaccine against leprosy, which has both immuno-prophylactic and laudable therapeutic properties. It cures ugly leprosy patients to normal beings without any ugly blemishes or scars, so much so that it is difficult to consider the cured person as having ever suffered from leprosy. It received the approval of Drugs Controller General of India and US FDA. It is passed on to a company for making it available to public. The vaccine is based on a cultivable atypical mycobacteria. The gene sequence of this mycobacteria is now known. It has been named as Mycobacterium indicus pranii (MIP). Pran is my family name and nii is the National institute of immunology, of which I was the Founder Director, where the final vaccine development took place. MIP is also highly effective for treatment of Category-II, “Difficult-to-treat” Tuberculosis. It is a potent invigorator of immune response. The company making it, is marketing it under different names for Psoriasis and some cancers It is being employed by the Department of Dermatology, All India Institute of Medical Sciences, New Delhi for impressive treatment of ugly ano-genital warts. We are using MIP as adjuvant in the recombinant anti-hCG Birth Control vaccine currently under development. A totally unforeseen application of MIP has been for treatment for Covid-19 patients as reported in 2 recent publications.